Standards & Regulation

One pharma company is working to pioneer safer drugs for use during pregnancy…

The lack of evidence available from pharma companies to guide care of pregnant women is ethically unacceptable.

Is pharma putting women and children last?

A recent review and meta-analysis highlights the huge impact of fake and substandard drugs.

“Right to Try” legislation may have compassion at its heart, but it does not do enough to ensure patient protection.

Fighting counterfeit medicines is a noble goal, but the financial burden of safety features may affect access to medicines in unintended ways.

Interest in cannabinoid drug development is growing. The potential market – and the opportunity to treat unmet patient needs – is enormous.

How will biopharmaceutical process development be affected by next-generation technologies?

Why are we still making life difficult for a growing patient population when solutions exist?

Do methods that compare newly approved drugs with those already on the market help cut healthcare costs?